Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Artelo Biosciences, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 6 | 8 | +2 |
| Shares | 39.3K | 52.5K | +13.2K (+33.6%) |
| Value | $78.4K | $76.4K | −$2.01K (−2.6%) |
New holders (4)
Institutions that held Artelo Biosciences, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 30,282 | $44.0K | 0.00% |
| UBS Group AG | 112 | $164 | 0.00% |
| The PNC Financial Services Group, Inc. | 71 | $104 | 0.00% |
| FMR LLC | 20 | $29 | 0.00% |
Sold out (2)
Institutions that held Artelo Biosciences, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Two Sigma Advisers, LP | 20,562 | $40.9K |
| JPMorgan Chase & Co | 304 | $611 |